U.K. Ophthalmic Drugs Market Size & Outlook, 2026-2033
- Pharmaceuticals
- Ophthalmology Drugs
- Ophthalmic Drugs Market Outlook
- Ophthalmology Drugs
Global Market
Related Markets
Ask a question about the ophthalmic drugs market
UK ophthalmic drugs market highlights
- The UK ophthalmic drugs market generated a revenue of USD 1,787.5 million in 2025 and is expected to reach USD 3,586.1 million by 2033.
- The UK market is expected to grow at a CAGR of 9.1% from 2026 to 2033.
- In terms of segment, anti-vegf agents was the largest revenue generating drug class in 2025.
- Gene & Cell Therapy is the most lucrative drug class segment registering the fastest growth during the forecast period.
Ophthalmic drugs market data book summary
| Market revenue in 2025 | USD 1,787.5 million |
| Market revenue in 2033 | USD 3,586.1 million |
| Growth rate | 9.1% (CAGR from 2026 to 2033) |
| Largest segment | Anti-vegf agents |
| Fastest growing segment | Gene & Cell Therapy |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Anti-VEGF agents, Anti-glaucoma, Anti-inflammatory, Anti-Allergy, Gene & Cell Therapy |
| Key market players worldwide | Pfizer Inc, Alcon Inc, Novartis AG ADR, Bausch Health Companies Inc, Merck & Co Inc, Regeneron Pharmaceuticals Inc, AbbVie Inc, Bayer AG, Genentech, Nicox SA Share from reverse split, Coherus BioSciences Inc |
Other key industry trends
- In terms of revenue, UK accounted for 4.3% of the global ophthalmic drugs market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany ophthalmic drugs market is projected to lead the regional market in terms of revenue in 2033.
- UK is the fastest growing regional market in Europe and is projected to reach USD 3,586.1 million by 2033.
In the UK, inherited retinal disorders are the major cause of blindness in the working-age population. Retinitis pigmentosa is the most prevalent inherited eye disorder, affecting around one in every 4,000 persons in the UK.
Moreover, according to data published by eyecare expert, Théa UK, an estimated 34% of the total population in the UK, representing one in every three people, is diagnosed with dry eye disease.
No credit card required*
Publish Date: Apr 16, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Ophthalmic Drugs Market Scope
Ophthalmic Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Alcon Inc | View profile | 25,315 | Chemin de Blandonnet 8, Royce Bedward, Vernier, Geneva, Switzerland, 1214 | www.alcon.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| Regeneron Pharmaceuticals Inc | View profile | 13,450 | 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 | www.regeneron.com |
| Bausch Health Companies Inc | View profile | 20,270 | 2150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8 | www.bauschhealth.com |
| Genentech | View profile | 10001+ | South San Francisco, California, United States, North America | gene.com |
| Coherus BioSciences Inc | View profile | 306 | 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, United States, 94065 | www.coherus.com |
U.K. Ophthalmic Drugs Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Ophthalmic Drugs Market Outlook will help companies and investors design strategic landscapes.
Anti-Vegf Agents was the largest segment with a revenue share of 39.13% in 2025.
Horizon Databook has segmented the U.K. ophthalmic drugs market based on anti-vegf agents, anti-glaucoma, anti-inflammatory, anti-allergy, gene & cell therapy covering the revenue growth of each sub-segment from 2021 to 2033.
In the UK, inherited retinal disorders are the major cause of blindness in the working-age population. Retinitis pigmentosa is the most prevalent inherited eye disorder, affecting around one in every 4,000 persons in the UK.
Moreover, according to data published by eyecare expert, Théa UK, an estimated 34% of the total population in the UK, representing one in every three people, is diagnosed with dry eye disease.
- U.K. Ophthalmic Drugs Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
- Anti-Allergy
- Anti-VEGF agents
- Anti-glaucoma
- Gene & Cell Therapy
- Others
- Anti-inflammatory
- U.K. Ophthalmic Drugs Market Disease Outlook (Revenue, USD Million , 2021-2033)
- Dry Eye
- Allergies
- Glaucoma
- Infection
- Retinal Disorders
- Uveitis
- Others
- U.K. Ophthalmic Drugs Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Topical
- Systemic
- Local Ocular
- U.K. Ophthalmic Drugs Market Dosage Type Outlook (Revenue, USD Million , 2021-2033)
- Gels
- Eye solutions & suspensions
- Capsules & Tablets
- Eye drops
- Ointments
- U.K. Ophthalmic Drugs Market Product Type Outlook (Revenue, USD Million , 2021-2033)
- OTC drugs
- Prescription
- U.K. Ophthalmic Drugs Market Drug Type Outlook (Revenue, USD Million , 2021-2033)
- Branded Drugs
- Generic Drugs
Reasons to subscribe to Ophthalmic Drugs Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Ophthalmic Drugs Market Outlook databook
- Our clientele includes a mix of Ophthalmic Drugs Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.K. Ophthalmic Drugs Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.K. Ophthalmic Drugs Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.K. Ophthalmic Drugs Market, 2021-2033 (US$M)
UK ophthalmic drugs market statistics, by drug class, 2021-2033 (US$M)
